Cytogenetic abnormalities in Acute Myeloid Leukemia in Sweden. A population based study.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Abstract

The impact of cytogenetic findings in AML was analyzed in the large population-based Swedish AML
registry. Karyotypic patterns differed by age: t(8;21), inv(16) and t(11q23) were more common in younger patients,
whereas loss of 5q, 7q and 17p, monosomal karyotype (MK) and complex karyotype (CK) were more common in
older patients. Patients with ≥5 chromosome abnormalities had worse overall survival than those with fewer
abnormalities or normal karyotype in all age groups. Loss of 5q, 7q and/or 17p had, in contrast to MK, a further
negative impact on survival. Multivariable analyses on risk factors in patients <80 years with cytogenetic
abnormalities and intensive treatment revealed that age and performance status had the most significant impact
on survival (both P<0.001), followed by sex (P=0.0135) and a karyotype including -7/del(7q) (P=0.048).
We compared outcome of AHD-AML and tAML, i.e., secondary (sAML) with de novo AML. The CR rates were
significantly lower but early death rates similar in sAML vs de novo AML. In a multivariable analysis, AHD-AML
(HR 1.51; 95% CI 1.26–1.79) and tAML (1.72; 1.38–2.15) were independent risk factors for poor survival. The
negative impact of AHD-AML and tAML on survival was highly age dependent with a considerable impact in
younger patients, but without independent prognostic value in the elderly.
The frequencies of unsuccessful cytogenetics (UC) and unperformed cytogenetics (UPC) were 2.1% and 2.0%,
respectively. The early death rates differed between the cytogenetic subgroups (P=0.006) with the highest rates in
patients with UC (14%) and UPC (12%) followed by high-risk (HR) AML, intermediate risk (IR) and standard risk
(SR) cases successfully karyotyped (8.6%, 5.9%, and 5.8%, respectively). The CR rate was lower in UC and UPC
and HR compared with the other risk groups (P<0.001). The 5-year OS rates were 25% for UC and 22% for UPC,
whereas the corresponding frequencies for SR, IR and HR AML patients without UC and UPC were 64%, 31%
and 15%, respectively. Lack of cytogenetic data translates into a poor prognosis.
To ascertain the clinical implications of high hyperdiploid (HH; 49–65 chromosomes) and triploid/tetraploid (TT;
>65 chromosomes) adult AML diagnosed 1997-2014, and 68 (1.9%) were HH (n=50)/TT (n=18). The OS was
similar between patients with HH/TT and CK AML (median 0.9 years vs. 0.6 years; P=0.082), whereas OS was
significantly longer (median 1.6 years; P=0.028) for IR AML. The OS was shorter for cases with HH than with TT
(median 0.6 years vs. 1.4 years; P=0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years vs.
1.1 years; P=0.044). HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence
of adverse aberrations seem to translate into a more favorable prognosis.
Also, among 23 patients (0.4 %) with trisomy 13 with a median age of 72 years (44-84), there was a striking male
predominance (80%) with AML-M0 subtype in 37% of patients. Therapy-related AML and MDS/MPN/AML were
present in 30% of patients. Median OS time was 9.6 months (95 % CI (3.5-13.7), and 13 months for other patients
(95% CI 11.7-14.04), which was almost identical as in previously published studies.

Detaljer

Författare
  • Vladimir Lazarevic
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Hematologi

Nyckelord

Originalspråkengelska
KvalifikationDoktor
Tilldelande institution
Handledare/Biträdande handledare
Tilldelningsdatum2016 jan 20
Förlag
  • Stam Cells Centrum (SCC)
Tryckta ISBN978-91-7619-227-6
StatusPublished - 2015
PublikationskategoriForskning

Nedladdningar

Ingen tillgänglig data

Relaterad forskningsoutput

Lazarevic, V., Hörstedt, A., Bertil Johansson, Antunovic, P., Billström, R., Derolf, A., Lehmann, S., Möllgård, L., Peterson, S., Stockelberg, D., Uggla, B., Vennström, L., Wahlin, A., Höglund, M. & Gunnar Juliusson, 2015, I : European Journal of Haematology. 94, 5, s. 419-423

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Lazarevic, V., Aldana Rosso, Gunnar Juliusson, Antunovic, P., Rangert-Derolf, Å., Lehmann, S., Möllgård, L., Uggla, B., Wennström, L., Wahlin, A., Höglund, M. & Bertil Johansson, 2015, I : American Journal of Hematology. 90, 9, s. 800-805

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Lazarevic, V., Hörstedt, A., Bertil Johansson, Antunovic, P., Billström, R., Derolf, A., Hulegårdh, E., Lehmann, S., Möllgård, L., Nilsson, C., Peterson, S., Stockelberg, D., Uggla, B., Wennström, L., Wahlin, A., Höglund, M. & Gunnar Juliusson, 2014, I : Blood Cancer Journal. 4, Feb 28, s. e188

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Visa alla (3)